Merck and its rivals make tens of billions of dollars a year from the mechanism and are ... regardless of PD-L1 expression. Junshi, Coherus' PD-1 inhibitor Loqtorzi scores in phase 3 liver cancer ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 ...

MCC primarily affects older adults, with its incidence rising exponentially with age, most commonly presenting between ages 70 and 80. It is exceptionally rare in younger individuals; data from ...

Why have these specific drugs become so popular? Well, checkpoint inhibitors can block mechanisms that tumors use to protect themselves from being attacked by immune cells. The PD-1 receptor is an ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...